Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hodgkin Disease × axatilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Leukemia, Myelomonocytic, Chronic 2 Primary Myelofibrosis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Graft vs Host Disease 1 Cholangiocarcinoma 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 192 fludarabine phosphate 120 Peripheral Blood Stem Cell Transplantation 106 Etoposide 106 Mycophenolic Acid 93 Filgrastim 91 Doxorubicin 84 Whole-Body Irradiation 82 Tacrolimus 79 Melphalan 78 Brentuximab Vedotin 77 Radiotherapy 73 Busulfan 73 fludarabine 66 Cyclosporine 66 Vinblastine 64 Rituximab 60 Dacarbazine 55 Granulocyte Colony-Stimulating Factor 53 Gemcitabine 52 Antilymphocyte Serum 51 Bleomycin 50 Methotrexate 47 Vincristine 46 Prednisone 45 Nivolumab 45 Cytarabine 43 Carmustine 36 pembrolizumab 35 Bendamustine Hydrochloride 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05723055 2025-11-26

NAHL

University of Utah

Phase 2 Recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡